Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Enhancing MHC-Independent T Cell Receptors Using Rational Protein Engineering

Jufang Chang, Jack Landmann, Yangdon Tenzin, John Warrington, Mehmet Emrah Selli, Tien-Ching Chang, Michael Slade, Deepesh Gupta, Nathan Singh

Blood (2023) 142 (Supplement 1): 354.

https://doi.org/10.1182/blood-2023-182154

Published: 2023

Journal Articles

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Michael Slade, Michael P. Rettig, Zachary David Crees, Neha Mehta-Shah, Todd A Fehniger, Amanda F Cashen, Iskra Pusic, Geoffrey L Uy, Peter Westervelt, John DiPersio, Armin Ghobadi

Blood (2023) 142 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2023-172439

Published: 2023

Journal Articles

Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias

Mariya Liyasova, Michael Slade, Julie Fortier, Ravi Vij, Mark Fiala, Liqiang Yang, Bin Ma

Blood (2023) 142 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2023-186583

Published: 2023

Journal Articles

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Michael Slade, Abir Khaled, Mark Fiala, Zac McDonald, Mariya Liyasova, Julie Fortier, Mark Zaydman, Sarah Kelley, Zachary David Crees, Mark A. Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2023) 142 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2023-172440

Published: 2023

Journal Articles

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Meaghan Ryan, Zachary David Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L Uy, Keith Stockerl-Goldstein

Blood (2023) 142 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2023-179604

Published: 2023

Journal Articles

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Blood (2023) 141 (26): 3153–3165.

https://doi.org/10.1182/blood.2023020100

Published: 2023

Includes: Supplemental data

Journal Articles

The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis

Blood (2022) 140 (20): 2101–2112.

https://doi.org/10.1182/blood.2022016194

Published: 2022

Includes: Supplemental data

Journal Articles

The Impact of Tocilizumab Treatment for Cytokine Release Syndrome on the Incidence of Blood Stream Infections after Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Elisa De Togni, Fei Wan, Michael Slade, Ramzi Abboud

Blood (2021) 138 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2021-147103

Published: 2021

Journal Articles

Impact of Donor Age and Relationship on Outcomes of Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Aaron Pruitt, Feng Gao, Elisa De Togni, Aaron Singareddy, Hunter Cochran, Sonia Godbole, Michael Slade, Ramzi Abboud

Blood (2021) 138 (Supplement 1): 2924.

https://doi.org/10.1182/blood-2021-149718

Published: 2021

Journal Articles

Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples

Michael Slade, MDMS, Michelle O'Laughlin, Robert S Fulton, Eric J. Duncavage, MD, Timothy J Ley, MD, Meagan A. Jacoby, MD, David H Spencer, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-133279

Published: 2020

Journal Articles

HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Joseph Rimando, MD, Michael Slade, MD MS, Feng Gao, PhD, Rizwan Romee, MD, Chang Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2018-99-112494

Published: 2018

Journal Articles

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Michael Slade, MDMS, Ramzi Abboud, MD BS, John F DiPersio, MD PhD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 4575.

https://doi.org/10.1182/blood.V130.Suppl_1.4575.4575

Published: 2017

Journal Articles

The Relationship between HLA Disparity and Clinical Outcomes in Peripheral Blood T Cell Replete Haploidentical Hematopoietic Cell Transplantation

Joseph Rimando, BS, Michael Slade, MDMS, Feng Gao, PhD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 4555.

https://doi.org/10.1182/blood.V130.Suppl_1.4555.4555

Published: 2017

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS

Eric Huselton, MD, Rizwan Romee, MD, Michael Slade, BA, Cory Jenson

Blood (2016) 128 (22): 2278.

https://doi.org/10.1182/blood.V128.22.2278.2278

Published: 2016

Journal Articles

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Se young Han, MD, Rizwan Romee, MD, Michael Slade, BA, Pavan Kumar Bhamidipati, MBBS, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Yu Tao, PhD

Blood (2016) 128 (22): 3477.

https://doi.org/10.1182/blood.V128.22.3477.3477

Published: 2016

Journal Articles

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

Ramzi Abboud, MD, Michael Slade, BA, Wenners Ballard, III, MD, Jesse Keller, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Camille N. Abboud, MD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Rizwan Romee, MD

Blood (2016) 128 (22): 3419.

https://doi.org/10.1182/blood.V128.22.3419.3419

Published: 2016

Journal Articles

Graft Lymphocyte Content Does Not Influence Outcomes after Peripheral Blood Haploidentical Transplants Using Post Transplant Cyclophosphamide (PTCy)

Steven H Borson, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Mark A. Schroeder, MD, Rizwan Romee, MD, Cory Jensen, BS

Blood (2016) 128 (22): 5883.

https://doi.org/10.1182/blood.V128.22.5883.5883

Published: 2016

Journal Articles

Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS

Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Geoffrey L. Uy, MD, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2016) 128 (22): 4658.

https://doi.org/10.1182/blood.V128.22.4658.4658

Published: 2016

Journal Articles

The Use of CD34 + -Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation

Michael Slade, BA, Scott R Goldsmith, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Todd A Fehniger, MD PhD, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2016) 128 (22): 4697.

https://doi.org/10.1182/blood.V128.22.4697.4697

Published: 2016

NARROW

Enhancing MHC-Independent T Cell Receptors Using Rational Protein Engineering

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis

The Impact of Tocilizumab Treatment for Cytokine Release Syndrome on the Incidence of Blood Stream Infections after Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Impact of Donor Age and Relationship on Outcomes of Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples

HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

The Relationship between HLA Disparity and Clinical Outcomes in Peripheral Blood T Cell Replete Haploidentical Hematopoietic Cell Transplantation

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

Graft Lymphocyte Content Does Not Influence Outcomes after Peripheral Blood Haploidentical Transplants Using Post Transplant Cyclophosphamide (PTCy)

Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS

The Use of CD34 + -Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only